Study Reported Overall Response Rate of 38%, and REVLIMID® (Lenalidomide) Was Well Tolerated
BOUDRY, Switzerland–(BUSINESS WIRE)–Dec. 11, 2011– Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced interim results of CLL-009, a study evaluating three starting doses of REVLIMID® (lenalidomide), followed by step-wise dose escalation as tolerated in patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. The findings were presented during the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA. Read more of this entry
Dosing Study Evaluates REVLIMID® in Previously Treated Patients with Chronic Lymphocytic Leukemia
Categories: Life Sciences Industry Network
NJTC TechWire
Daily updates about the region's most tech savvy companies
Trackbacks/Pingbacks
[...] from: Dosing Study Evaluates REVLIMID® in Previously Treated Patients with Chronic Lymphocytic Leukemia Tags: archives, careers, digital-video, energy, health, oracle, prevention, revlimid®, technology, [...]